Metraipolis › archive › dc_16c6bb168e02

TGFB2 as a Prognostic Biomarker Associated with Myeloid-Enriched, Multi-Checkpoint-Activated Immunosuppression in Diffuse Glioma: A Multi-Cohort… — Europe PMC PMID:42449636

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42449636
DOI
10.3390/cancers18132092
License (as archived)
solo-consultazione
Archived
2026-10-31T08:18:27.488Z
SHA-256 of the archived text
58e019c26920730b8891147f30d9acda4749d1a675a37713098ee54b0f2b6def
Stable URL of this page
https://metraipolis.com/documento/dc_16c6bb168e02

How to cite

TGFB2 as a Prognostic Biomarker Associated with Myeloid-Enriched, Multi-Checkpoint-Activated Immunosuppression in Diffuse Glioma: A Multi-Cohort… — Europe PMC PMID:42449636 — Europe PMC (en), https://europepmc.org/article/MED/42449636 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_16c6bb168e02 (Metraipolis archive dc_16c6bb168e02, sha256 58e019c26920730b8891147f30d9acda4749d1a675a37713098ee54b0f2b6def)
BibTeX
@misc{dc16c6bb168e02,
  title = {TGFB2 as a Prognostic Biomarker Associated with Myeloid-Enriched, Multi-Checkpoint-Activated Immunosuppression in Diffuse Glioma: A Multi-Cohort… — Europe PMC PMID:42449636},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42449636},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_16c6bb168e02; sha256 58e019c26920730b8891147f30d9acda4749d1a675a37713098ee54b0f2b6def},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42449636. Agents can read the archived copy with the MCP tool read_document.